| Followers | 63 |
| Posts | 8909 |
| Boards Moderated | 0 |
| Alias Born | 03/31/2016 |
Wednesday, April 06, 2022 10:44:16 AM
Ridiculous. People are just panic machines these days - they sold it UNDER what it was with the good news lol...I actually thought this could happen. Absolutely insane. To say it's a diluting pig is absolute nonsense. Don't listen to that - 200 million AS is a very small share structure. If (and it's a big IF still) this got FDA approval, $20 would be in play over time IMO.
Recent CTXR News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/06/2026 08:15:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/31/2026 08:32:33 PM
- Citius Oncology Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical Development • PR Newswire (US) • 03/31/2026 01:11:00 PM
- Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR™ in Discussions with Leading Cutaneous Lymphoma Experts • PR Newswire (US) • 03/24/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/10/2026 01:03:55 PM
- Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers • PR Newswire (US) • 03/10/2026 12:47:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2026 02:25:21 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 02/24/2026 01:04:14 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 02/24/2026 01:02:12 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 02/24/2026 01:00:41 PM
- Citius Pharmaceuticals, Inc. Secures $3.8 million through New Jersey Economic Development Program • PR Newswire (US) • 02/24/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2026 01:30:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/13/2026 01:00:57 PM
- Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™ • PR Newswire (US) • 02/13/2026 01:00:00 PM
- Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™ • PR Newswire (US) • 02/13/2026 01:00:00 PM
- Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Uniphar • PR Newswire (US) • 02/11/2026 01:00:00 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 01/28/2026 09:30:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/23/2025 09:49:06 PM
- Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update • PR Newswire (US) • 12/23/2025 09:30:00 PM
- Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update • PR Newswire (US) • 12/23/2025 09:30:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 12/23/2025 09:21:08 PM
- Citius Oncology Shares Sink After Announcing $18M Fundraising Deal • IH Market News • 12/09/2025 03:19:37 PM
- Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules • PR Newswire (US) • 12/09/2025 01:30:00 PM
